Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma

[1]  Chia-Hung Chen,et al.  PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs , 2021, Oncogene.

[2]  Bo-Kyung Kim,et al.  Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer , 2021, Cancers.

[3]  Yih-Leong Chang,et al.  Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer. , 2021, Cancer letters.

[4]  M. Karin,et al.  Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor—MIG6 Axis , 2021, Cancers.

[5]  B. Győrffy,et al.  Pancancer survival analysis of cancer hallmark genes , 2020, Scientific Reports.

[6]  J. Abdolalizadeh,et al.  Hsp70 in cancer: A double agent in the battle between survival and death , 2020, Journal of cellular physiology.

[7]  L. Senggunprai,et al.  Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells. , 2020, The American journal of Chinese medicine.

[8]  Zhaowu Ma,et al.  The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells , 2020, Frontiers in Oncology.

[9]  Yulin Huang,et al.  Curcumin Derivative C086 Combined with Cisplatin Inhibits Proliferation of Osteosarcoma Cells , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[10]  P. Hershberger,et al.  Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer , 2020, Frontiers in Genetics.

[11]  P. Oteiza,et al.  The Inhibitory Effect of ECG and EGCG Dimeric Procyanidins on Colorectal Cancer Cells Growth is Associated with Their Actions at Lipid Rafts and the Inhibition of the Epidermal Growth Factor Receptor Signaling. , 2020, Biochemical pharmacology.

[12]  C. D. Dela Cruz,et al.  Lung Cancer 2020: Epidemiology, Etiology, and Prevention. , 2020, Clinics in chest medicine.

[13]  Jacob Josiah Santiago Alvarez,et al.  Genomic landscape of lung adenocarcinoma in East Asians , 2020, Nature Genetics.

[14]  Ying Lv,et al.  Curcumin enhances radiosensitization of nasopharyngeal carcinoma by regulating circRNA network , 2019, Molecular carcinogenesis.

[15]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[16]  Wei-Chung Cheng,et al.  DriverDBv3: a multi-omics database for cancer driver gene research , 2019, Nucleic Acids Res..

[17]  Min Liu,et al.  Curcumin inhibits cell proliferation and migration in NSCLC through a synergistic effect on the TLR4/MyD88 and EGFR pathways , 2019, Oncology reports.

[18]  C. Porta,et al.  Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy , 2019, International journal of molecular sciences.

[19]  P. Jänne,et al.  Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. , 2019, Cancer discovery.

[20]  Ping Chen,et al.  Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death , 2019, Journal of Experimental & Clinical Cancer Research.

[21]  Zhao-ying Sheng,et al.  Radiosensitization effects of curcumin plus cisplatin on non-small cell lung cancer A549 cells , 2019, Oncology letters.

[22]  Bradley P. Coe,et al.  Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR‐Mediated Lung Tumorigenesis , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Jaewhan Song,et al.  Multifaceted C-terminus of HSP70-interacting protein regulates tumorigenesis via protein quality control , 2019, Archives of Pharmacal Research.

[24]  M. Schachner,et al.  Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor , 2018, Cancers.

[25]  Kwok-Kin Wong,et al.  Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. , 2018, Cancer cell.

[26]  The Gene Ontology Consortium,et al.  The Gene Ontology Resource: 20 years and still GOing strong , 2018, Nucleic Acids Res..

[27]  L. Luo,et al.  EGFR-TKI-induced HSP70 degradation and BER suppression facilitate the occurrence of the EGFR T790 M resistant mutation in lung cancer cells. , 2018, Cancer letters.

[28]  E. Leung,et al.  Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells , 2018, Front. Pharmacol..

[29]  Yunpeng Liu,et al.  Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients , 2018, Clinical Cancer Research.

[30]  S. Cascinu,et al.  Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. , 2018, Critical reviews in oncology/hematology.

[31]  Jai-Sing Yang,et al.  Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study , 2017, International journal of oncology.

[32]  T. Bivona,et al.  Understanding and targeting resistance mechanisms in NSCLC , 2017, Nature Reviews Cancer.

[33]  Yingjie Guo,et al.  Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling , 2017, Oncotarget.

[34]  F. Wang,et al.  Liposomal honokiol induced lysosomal degradation of Hsp90 client proteins and protective autophagy in both gefitinib-sensitive and gefitinib-resistant NSCLC cells. , 2017, Biomaterials.

[35]  M. Cromie,et al.  Epigallocatechin‐3‐gallate augments the therapeutic effects of benzo[a]pyrene‐mediated lung carcinogenesis , 2017, BioFactors.

[36]  C. Patra,et al.  Gold nanoparticles–conjugated quercetin induces apoptosis via inhibition of EGFR/PI3K/Akt–mediated pathway in breast cancer cell lines (MCF‐7 and MDA‐MB‐231) , 2017, Cell biochemistry and function.

[37]  Hui-Yi Lin,et al.  New bis(hydroxymethyl) alkanoate curcuminoid derivatives exhibit activity against triple-negative breast cancer in vitro and in vivo. , 2017, European journal of medicinal chemistry.

[38]  E. Spisni,et al.  EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion , 2017, Bioscience reports.

[39]  D. Yiannakis,et al.  EGFR targeted therapy in lung cancer; an evolving story , 2017, Respiratory medicine case reports.

[40]  S. Ceri,et al.  TCGA2BED: extracting, extending, integrating, and querying The Cancer Genome Atlas , 2017, BMC Bioinformatics.

[41]  M. Tiseo,et al.  Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. , 2016, Translational lung cancer research.

[42]  M. Hung,et al.  The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer , 2016, Cancer and Metastasis Reviews.

[43]  Yuquan Wei,et al.  Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways , 2016, Oncotarget.

[44]  Yeon-Hee Park,et al.  The E3 ubiquitin ligase CHIP selectively regulates mutant epidermal growth factor receptor by ubiquitination and degradation. , 2016, Biochemical and biophysical research communications.

[45]  Jianxing He,et al.  EGFR gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis , 2016, Journal of Investigative Medicine.

[46]  Ameya R. Kirtane,et al.  Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors , 2016, Oncotarget.

[47]  G. Zhai,et al.  Oral bioavailability of curcumin: problems and advancements , 2016, Journal of drug targeting.

[48]  N. Lu,et al.  Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. , 2015, Lung cancer.

[49]  Chi-Yuan Chen,et al.  Sulforaphane attenuates EGFR signaling in NSCLC cells , 2015, Journal of Biomedical Science.

[50]  S. Katiyar,et al.  Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor , 2015, Oncotarget.

[51]  T. Maeda,et al.  Deguelin Induces Apoptosis by Targeting Both EGFR-Akt and IGF1R-Akt Pathways in Head and Neck Squamous Cell Cancer Cell Lines , 2015, BioMed research international.

[52]  S. Digumarthy,et al.  Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. , 2015, Cancer discovery.

[53]  Pan‐Chyr Yang,et al.  Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects. , 2015, Bioorganic & medicinal chemistry.

[54]  Hao Jiang,et al.  Resveratrol inhibits glioma cell growth via targeting oncogenic microRNAs and multiple signaling pathways. , 2015, International journal of oncology.

[55]  P. Elumalai,et al.  Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway. , 2014, The Journal of nutritional biochemistry.

[56]  William Pao,et al.  Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. , 2014, Cancer discovery.

[57]  H. Kampinga,et al.  BAG3 induces the sequestration of proteasomal clients into cytoplasmic puncta , 2014, Autophagy.

[58]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[59]  F. Gao,et al.  Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway. , 2014, Oncology reports.

[60]  Hong Wang,et al.  Honokiol Enhances Paclitaxel Efficacy in Multi-Drug Resistant Human Cancer Model through the Induction of Apoptosis , 2014, PloS one.

[61]  Yan Peng,et al.  Novel compound PS-101 exhibits selective inhibition in non-small-cell lung cancer cell by blocking the EGFR-driven antiapoptotic pathway. , 2013, Biochemical pharmacology.

[62]  R. Mehta,et al.  Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells , 2013, PloS one.

[63]  Ning Leng,et al.  EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments , 2013, Bioinform..

[64]  Te-Chang Lee,et al.  Multidrug-resistant cells overexpressing P-glycoprotein are susceptible to DNA crosslinking agents due to attenuated Src/nuclear EGFR cascade-activated DNA repair activity , 2013, Oncogene.

[65]  S. Safe,et al.  Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs , 2012, BMC Cancer.

[66]  A. Verma,et al.  Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF‐κB signaling pathways , 2012, International journal of cancer.

[67]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[68]  Jeremy J. W. Chen,et al.  Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy , 2011, PloS one.

[69]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[70]  H. Hieronymus,et al.  FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR , 2011, Nature.

[71]  H. Schild,et al.  The Hsc/Hsp70 Co-Chaperone Network Controls Antigen Aggregation and Presentation during Maturation of Professional Antigen Presenting Cells , 2011, PloS one.

[72]  Jie Gao,et al.  Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas , 2010, BMC Cancer.

[73]  J. H. Kim,et al.  Quercetin suppresses HeLa cell viability via AMPK‐induced HSP70 and EGFR down‐regulation , 2010, Journal of cellular physiology.

[74]  S. Safe,et al.  Drugs that Target Specificity Proteins Downregulate Epidermal Growth Factor Receptor in Bladder Cancer Cells , 2010, Molecular Cancer Research.

[75]  Daniel B. Neill,et al.  Honokiol Inhibits Epidermal Growth Factor Receptor Signaling and Enhances the Antitumor Effects of Epidermal Growth Factor Receptor Inhibitors , 2010, Clinical Cancer Research.

[76]  F. Zunino,et al.  The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition , 2010, Cellular and Molecular Life Sciences.

[77]  M. Meyerson,et al.  PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. , 2009, Cancer research.

[78]  Yueh-Fu Fang,et al.  Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients. , 2008, Lung cancer.

[79]  B. Zhan,et al.  RNA Interference-Mediated Silencing of the Hsp70 Gene Inhibits Human Gastric Cancer Cell Growth and Induces Apoptosis in Vitro and in Vivo , 2008 .

[80]  M. Hung,et al.  Survival of cancer cells is maintained by EGFR independent of its kinase activity. , 2008, Cancer cell.

[81]  M. A. Akbarsha,et al.  Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. , 2008, Anticancer research.

[82]  R. Rosengren,et al.  The combination of epigallocatechin gallate and curcumin suppresses ERα‐breast cancer cell growth in vitro and in vivo , 2007, International journal of cancer.

[83]  M. Fukuoka,et al.  Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. , 2007, Cancer research.

[84]  Michele D. Sobolewski,et al.  Sulforaphane induces cell type–specific apoptosis in human breast cancer cell lines , 2007, Molecular Cancer Therapeutics.

[85]  Dimitra Keramisanou,et al.  Involvement of heat shock protein-70 in the mechanism of hydrogen peroxide-induced DNA damage: the role of lysosomes and iron. , 2007, Free radical biology & medicine.

[86]  Y. Jeon,et al.  Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. , 2006, Lung cancer.

[87]  J. Greif,et al.  Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. , 2006, Anticancer research.

[88]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[89]  J. Luketich,et al.  Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. , 2006, American journal of clinical pathology.

[90]  M. Tsao,et al.  Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[92]  Hui You,et al.  Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. , 2005, Cancer research.

[93]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[94]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  M Paesmans,et al.  The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis , 2002, European Respiratory Journal.

[96]  O. Colhoun.  Switch , 2019, Springer Reference Medizin.

[97]  L. Paz-Ares,et al.  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[98]  Longyu Jin,et al.  Resveratrol mediates cell cycle arrest and cell death in human esophageal squamous cell carcinoma by directly targeting the EGFR signaling pathway. , 2017, Oncology letters.

[99]  J. Lin,et al.  Epigallocatechin gallate inhibits the growth of salivary adenoid cystic carcinoma cells via the EGFR/Erk signal transduction pathway and the mitochondria apoptosis pathway. , 2017, Neoplasma.

[100]  M. Hung,et al.  Regulation of therapeutic resistance in cancers by receptor tyrosine kinases. , 2016, American journal of cancer research.